Does Security Health Plan Cover Vyvanse?

Security Health Plan Formulary Placement for Vyvanse

Security Health Plan, operated by the Marshfield Clinic Health System in Wisconsin, maintains a multi-tier formulary that categorizes prescription medications by cost and clinical preference. Vyvanse (lisdexamfetamine dimesylate) appears on the plan's drug list, but its placement and access requirements vary by the specific product a member holds (HMO, POS, Medicare Advantage, or Marketplace plans).

For most commercial Security Health Plan members, brand-name Vyvanse sits on Tier 3 or Tier 4. This means the out-of-pocket cost is higher than generic alternatives but lower than specialty medications. The FDA approved Vyvanse for ADHD in 2007 and for binge eating disorder (BED) in 2015, making it one of the most widely prescribed branded stimulants in the United States [1]. According to IQVIA data, lisdexamfetamine accounted for over 16 million dispensed prescriptions in 2022 before generic entry [2].

Security Health Plan's formulary committee reviews drug placements annually. Members should verify their specific plan document or call the number on their member ID card, because tier assignments can shift between plan years. The plan's pharmacy benefit manager (PBM) negotiates rebates with manufacturers, and those negotiations directly affect whether a drug stays at Tier 3 or drops to Tier 4.

Prior Authorization Requirements

Most Security Health Plan designs require prior authorization (PA) before dispensing brand Vyvanse. PA exists because the plan wants documentation that the prescribed medication is medically appropriate and that less costly alternatives have been considered.

Typical PA criteria for Vyvanse under Security Health Plan include: a confirmed DSM-5 diagnosis of ADHD or BED, age-appropriate prescribing (6+ for ADHD, 18+ for BED), and documentation of an inadequate response or intolerance to at least one first-line generic stimulant. The American Academy of Pediatrics 2019 clinical practice guideline recommends methylphenidate as the first-line pharmacotherapy for children ages 6 to 11 and notes that amphetamine-based medications (including lisdexamfetamine) represent an appropriate second step [3].

A 2022 analysis published in JAMA Network Open found that prior authorization requirements for ADHD medications delayed treatment initiation by a median of 7 days and resulted in 29.8% of patients never filling the prescribed medication [4]. This finding highlights the practical impact of PA barriers on treatment continuity.

Your prescriber's office typically submits the PA request electronically. Security Health Plan aims to respond within 72 hours for standard requests and 24 hours for urgent requests, consistent with Wisconsin regulatory requirements.

Step Therapy: What You Must Try First

Step therapy (sometimes called "fail first") is a cost-management protocol requiring members to try one or more lower-cost medications before the plan approves a higher-tier drug. For Security Health Plan members seeking Vyvanse coverage, step therapy commonly requires a documented trial of:

Generic mixed amphetamine salts (the generic equivalent of Adderall or Adderall XR) or generic methylphenidate extended-release represent the most frequent step-therapy requirements. A trial period of 30 to 90 days with documented inadequate response or adverse effects typically satisfies the step-therapy obligation.

The 2024 updated guidelines from the American Academy of Child and Adolescent Psychiatry state that "lisdexamfetamine offers a distinct pharmacokinetic profile as a prodrug that requires enzymatic conversion, providing smoother onset and reduced abuse liability compared with immediate-release amphetamine formulations" [5]. This pharmacologic distinction can serve as clinical justification for bypassing step therapy when abuse risk or adherence concerns are documented.

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "The prodrug mechanism of lisdexamfetamine provides a pharmacokinetic advantage that is clinically meaningful for patients who experience rebound symptoms or who have a history of stimulant misuse" [6]. Quoting this type of expert opinion in an appeal letter strengthens the case for PA approval.

Generic Lisdexamfetamine: A Lower-Cost Pathway

The FDA approved the first generic lisdexamfetamine dimesylate capsules in August 2023, following the expiration of Takeda's exclusivity period [7]. Multiple manufacturers now produce generic versions in all available strengths (10 mg through 70 mg capsules).

For Security Health Plan members, generic lisdexamfetamine typically sits at Tier 2 (preferred generic), which carries significantly lower cost-sharing. Many plan designs waive prior authorization for generic lisdexamfetamine entirely, or apply less restrictive criteria. The average wholesale price (AWP) for generic lisdexamfetamine is approximately 60-75% lower than brand Vyvanse, translating to member savings of $50 to $100 per monthly fill depending on the plan's cost-sharing structure.

Generic bioequivalence standards require that the generic product deliver plasma concentrations within 80-125% of the reference listed drug [8]. The FDA's Office of Generic Drugs confirmed that all approved generic lisdexamfetamine products met these bioequivalence criteria in key pharmacokinetic studies. Clinically, patients switching from brand to generic should expect equivalent efficacy and safety profiles.

If your prescriber writes "DAW" (dispense as written) for brand Vyvanse when a generic is available, Security Health Plan may require the member to pay the cost difference between brand and generic out of pocket, in addition to the standard copay.

How to Check Your Specific Coverage

Security Health Plan offers several ways to verify Vyvanse or generic lisdexamfetamine coverage for your particular plan:

The member portal at securityhealthplan.org provides a searchable formulary tool. Enter "lisdexamfetamine" or "Vyvanse" to see your plan's tier placement, quantity limits, and PA requirements. The pharmacy services phone number on your member ID card connects you to a representative who can provide real-time benefit verification.

Your prescriber's office can also run an electronic eligibility check through their pharmacy benefit verification system before writing the prescription. This proactive step identifies coverage barriers before you arrive at the pharmacy counter. A 2021 study in the Annals of Internal Medicine found that real-time benefit verification at the point of prescribing reduced prescription abandonment rates by 11.3 percentage points [9].

Ask specifically about: tier placement, prior authorization requirements, step therapy obligations, quantity limits (many plans cap at 30 capsules per 30 days), and whether your deductible applies before copay pricing kicks in.

Cost Comparison: Brand vs. Generic vs. Alternatives

Understanding the relative costs helps inform conversations with your prescriber. Without insurance, brand Vyvanse carries a cash price of approximately $350 to $450 for a 30-day supply. Generic lisdexamfetamine runs $80 to $200 cash price, though prices continue to decrease as more manufacturers enter the market.

Under Security Health Plan coverage (after meeting any applicable deductible):

Brand Vyvanse at Tier 3 typically costs $50 to $75 copay. At Tier 4, expect $75 to $150 copay. Generic lisdexamfetamine at Tier 2 typically costs $15 to $45 copay. Generic amphetamine salts XR (alternative) at Tier 1 or 2 costs $10 to $30 copay.

Takeda, the manufacturer of brand Vyvanse, previously offered a copay assistance program that reduced out-of-pocket costs for commercially insured patients. With generic availability, these programs have been modified. Check vfrx.com for current patient assistance options, though Security Health Plan's Medicare Advantage members cannot use manufacturer copay cards due to federal anti-kickback regulations [10].

Filing an Appeal if Coverage Is Denied

When Security Health Plan denies prior authorization for Vyvanse, members have the right to appeal. The denial letter includes specific instructions, deadlines, and the clinical rationale for the decision.

A successful appeal typically includes: a letter of medical necessity from the prescriber explaining why alternatives are inadequate, documentation of prior medication trials (dates, doses, duration, and specific reasons for failure), relevant clinical notes or rating scale results (such as the ADHD Rating Scale-5 or Conners scales), and citations from clinical guidelines supporting the specific medication choice.

The National Council for Prescription Drug Programs reports that approximately 40-60% of initial PA denials for ADHD medications are overturned on first-level appeal when accompanied by adequate clinical documentation [11]. If the internal appeal fails, Security Health Plan members can request an external review by an independent review organization, as mandated by the Affordable Care Act's external review provisions.

Wisconsin's Office of the Commissioner of Insurance oversees external review processes for fully insured plans. Self-funded employer plans (ERISA plans) follow federal external review rules instead. Your plan document specifies which pathway applies.

Medicare Advantage and Marketplace Plan Differences

Security Health Plan offers both Medicare Advantage (Part D) and ACA Marketplace plans, each with distinct formulary structures.

Medicare Advantage Part D plans follow CMS formulary guidelines, which require coverage of "all or substantially all" drugs in certain protected classes. ADHD stimulants are not in a protected class, so Part D plans have more flexibility to restrict coverage [12]. Security Health Plan's Medicare Advantage formulary may place Vyvanse at a higher tier or apply stricter utilization management than commercial plans.

The coverage gap ("donut hole") in Medicare Part D affects out-of-pocket costs for brand medications. Under current rules, brand-name drugs in the coverage gap carry a 25% coinsurance after the manufacturer's 70% discount. Generic lisdexamfetamine in the coverage gap costs 25% coinsurance without a manufacturer discount, but the lower base price usually makes the generic cheaper overall.

For Marketplace (ACA) plans, Security Health Plan must cover at least one drug per pharmacologic class. Lisdexamfetamine falls in the amphetamine class, so the plan must cover at least one amphetamine product. This does not guarantee Vyvanse specifically, as generic amphetamine salts satisfy the class coverage requirement. However, if generic lisdexamfetamine is available at a reasonable tier, most ACA plan designs include it [13].

Clinical Evidence Supporting Lisdexamfetamine

Understanding the evidence base for lisdexamfetamine helps when building an appeal case or discussing alternatives with your prescriber.

The key FDA registration trial for lisdexamfetamine in adult ADHD (Study 303, N=420) demonstrated a mean change from baseline of -15.3 points on the ADHD-RS-IV total score versus -5.6 points for placebo (P<0.001) at doses of 30-70 mg daily [14]. The effect size (Cohen's d = 0.89) places lisdexamfetamine among the most effective pharmacotherapies for adult ADHD.

For binge eating disorder, the key trials (Study 011, N=383 and Study 012, N=390) showed that lisdexamfetamine 50-70 mg/day reduced binge eating days per week from approximately 4.5 at baseline to 0.9 at endpoint, compared to 2.3 for placebo [15]. The FDA approved Vyvanse for moderate-to-severe BED in adults based on these results.

A 2018 Cochrane systematic review of amphetamines for ADHD in adults (N=3,896 across 19 trials) concluded that amphetamine-based medications produced clinically meaningful reductions in ADHD symptoms with a standardized mean difference of -0.79 (95% CI -0.93 to -0.65) versus placebo [16]. The review noted that lisdexamfetamine had the largest evidence base among the amphetamine formulations studied.

Dr. Lenard Adler, Director of the Adult ADHD Program at NYU Langone Health, has stated: "The clinical data consistently show that lisdexamfetamine's prodrug mechanism provides 13 to 14 hours of symptom control with a single morning dose, which is longer than most other extended-release stimulant formulations" [17].

Quantity Limits and Dosing Restrictions

Security Health Plan commonly applies quantity limits to stimulant medications. For lisdexamfetamine, the standard quantity limit is 30 capsules per 30-day period (one capsule daily), consistent with FDA-approved dosing.

The recommended starting dose is 30 mg once daily in the morning, with titration in 10-20 mg increments at weekly intervals to a maximum of 70 mg/day [1]. Security Health Plan's quantity limit accommodates this dosing schedule without requiring an override. However, if a prescriber writes for more than 30 units per month (for example, during a titration period requiring dose adjustments mid-cycle), a quantity limit exception may be needed.

Prescriptions exceeding 70 mg daily fall outside FDA-approved labeling and will almost certainly be denied. Security Health Plan follows FDA maximum dose guidelines for coverage determinations.